Magdalena Szmyrka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Szmyrka has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jakub Mastalerz
Faculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland
3 shared publications - Adam Reich
Department of Dermatology, Faculty of Medicine, Medical College, University of Rzeszow, Rzeszow, Poland
1 shared publication - Alicja Dąbrowska
Faculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland
1 shared publication Amelia Pielech
Student, Faculty of Medicine, Wroclaw Medical University, Poland
1 shared publication- Dominik Samotij
University of Rzeszów
1 shared publication Elżbieta Ostańska
Medical College of Rzeszow University
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by Medical University of Silesia in Katowice in Annales Academiae Medicae Silesiensis
Hematological malignancies and autoimmune hemolytic anemia in systemic lupus erythematosus patients: A literature review
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and a wide spectrum of clinical manifestations, including significant hematological involvement. The objective of this review was to summarize the epidemiology, pathogenic mechanisms, and treatment approaches for hematological malignancies (HMs) and autoimmune hemolytic anemia (AIHA) in patients with SLE, integrating recent advances in diagnosis and therapy. We conducted a narrative review of meta-analyses, large population-based studies, and translational research addressing lymphoma, leukemia, multiple myeloma, and AIHA in the context of SLE. Findings consistently demonstrate an increased standardized incidence ratio (SIR) for HMs, particularly non-Hodgkin’s lymphoma (SIR ≈ 5.7), with elevated risks also reported for Hodgkin lymphoma, leukemias (acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia), and multiple myeloma (SIR ≈ 1.5). Pathogenesis is multifactorial, involving chronic immune activation, Epstein-Barr virus reactivation, oxidative stress, impaired DNA repair, and cumulative exposure to alkylating agents. AIHA, most commonly warm-antibody mediated, represents an additional source of morbidity, often complicating treatment decisions. Corticosteroids remain the first-line therapy, while refractory disease benefits from rituximab or cytotoxic immunosuppressants. Novel therapeutic strategies, including complement inhibitors (sutimlimab, pegcetacoplan), Bruton tyrosine kinase inhibitors, and neonatal Fc receptor antagonists, are emerging as promising options to reduce relapse rates and steroid dependence. Early recognition, individualized immunosuppressive regimens, and incorporation of targeted therapies may improve survival and long-term outcomes in this high-risk population.
- 8 June 2026
- Published by Medical University of Silesia in Katowice in Annales Academiae Medicae Silesiensis
Open AccessHematological malignancies and autoimmune hemolytic anemia in systemic lupus erythematosus patients: A literature review
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and a wide spectrum of clinical manifestations, including significant hematological involvement. The objective of this review was to summarize the epidemiology, pathogenic mechanisms, and treatment approaches for hematological malignancies (HMs) and autoimmune hemolytic anemia (AIHA) in patients with SLE, integrating recent advances in diagnosis and therapy. We conducted a narrative review of meta-analyses, large population-based studies, and translational research addressing lymphoma, leukemia, multiple myeloma, and AIHA in the context of SLE. Findings consistently demonstrate an increased standardized incidence ratio (SIR) for HMs, particularly non-Hodgkin’s lymphoma (SIR ≈ 5.7), with elevated risks also reported for Hodgkin lymphoma, leukemias (acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia), and multiple myeloma (SIR ≈ 1.5). Pathogenesis is multifactorial, involving chronic immune activation, Epstein-Barr virus reactivation, oxidative stress, impaired DNA repair, and cumulative exposure to alkylating agents. AIHA, most commonly warm-antibody mediated, represents an additional source of morbidity, often complicating treatment decisions. Corticosteroids remain the first-line therapy, while refractory disease benefits from rituximab or cytotoxic immunosuppressants. Novel therapeutic strategies, including complement inhibitors (sutimlimab, pegcetacoplan), Bruton tyrosine kinase inhibitors, and neonatal Fc receptor antagonists, are emerging as promising options to reduce relapse rates and steroid dependence. Early recognition, individualized immunosuppressive regimens, and incorporation of targeted therapies may improve survival and long-term outcomes in this high-risk population.
- Open Access
- 20 May 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (5) , 905-918
Gastrointestinal manifestations of systemic lupus erythematosus (SLE): A comprehensive literature review
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a broad spectrum of clinical manifestations, including gastrointestinal (GI) involvement. Although the joints, skin, and kidneys are most commonly affected, GI manifestations are frequently underrecognized despite their potential to significantly influence patient outcomes. Eleven major GI manifestations have been identified and described: oral ulcers, lupus enteritis (LE), lupus peritonitis (LP), mesenteric vasculitis, mesenteric thrombosis, protein-losing enteropathy (PLE), intestinal pseudo-obstruction (IPO), lupus pancreatitis, lupus hepatitis (LH), gastroesophageal reflux disease (GERD), and medication-related adverse effects. These manifestations may present with nonspecific symptoms, such as abdominal pain, diarrhea, vomiting, and weight loss, which often complicate timely diagnosis. Imaging modalities, particularly contrast-enhanced computed tomography, together with serological markers, including antinuclear antibodies (ANA) and complement levels, play a central role in diagnosis. Corticosteroids remain the cornerstone of treatment, whereas immunosuppressive agents and biologic therapies are reserved for refractory cases. Medication-induced GI adverse effects, particularly those associated with glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive agents such as azathioprine (AZA) and cyclophosphamide (CPA), also represent important contributors to GI pathology in patients with SLE. Gastrointestinal involvement in SLE is heterogeneous and may be severe. Increased awareness, early recognition, and individualized treatment strategies are essential for improving patient outcomes. Further research is required to establish standardized diagnostic criteria and therapeutic guidelines for GI manifestations in SLE.
- 20 May 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (5) , 905-918
Open AccessGastrointestinal manifestations of systemic lupus erythematosus (SLE): A comprehensive literature review
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a broad spectrum of clinical manifestations, including gastrointestinal (GI) involvement. Although the joints, skin, and kidneys are most commonly affected, GI manifestations are frequently underrecognized despite their potential to significantly influence patient outcomes. Eleven major GI manifestations have been identified and described: oral ulcers, lupus enteritis (LE), lupus peritonitis (LP), mesenteric vasculitis, mesenteric thrombosis, protein-losing enteropathy (PLE), intestinal pseudo-obstruction (IPO), lupus pancreatitis, lupus hepatitis (LH), gastroesophageal reflux disease (GERD), and medication-related adverse effects. These manifestations may present with nonspecific symptoms, such as abdominal pain, diarrhea, vomiting, and weight loss, which often complicate timely diagnosis. Imaging modalities, particularly contrast-enhanced computed tomography, together with serological markers, including antinuclear antibodies (ANA) and complement levels, play a central role in diagnosis. Corticosteroids remain the cornerstone of treatment, whereas immunosuppressive agents and biologic therapies are reserved for refractory cases. Medication-induced GI adverse effects, particularly those associated with glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive agents such as azathioprine (AZA) and cyclophosphamide (CPA), also represent important contributors to GI pathology in patients with SLE. Gastrointestinal involvement in SLE is heterogeneous and may be severe. Increased awareness, early recognition, and individualized treatment strategies are essential for improving patient outcomes. Further research is required to establish standardized diagnostic criteria and therapeutic guidelines for GI manifestations in SLE.
- 12 January 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (3) , 320-328
Lupus mastitis heralding macrophage activation syndrome: Case report and systematic review of the literature
Objective: The purpose of this systematic review study was to showcase diagnostic challenges posed by lupus mastitis (LM). Methods: Here we report a case of a 47-year- old Caucasian female with LM heralding systemic lupus erythematosus (SLE) complicated by macrophage activation syndrome (MAS), in the light of a systematic review of the literature on LM. Results: Including our patient, we identified 32 case reports of patients with LM in the course of SLE. Only in 6 cases, including ours, LM preceded SLE diagnosis. Ours is the first ever published case report of LM heralding MAS. Conclusion: LM in the course of SLE is rare and published data is very limited. Diagnosis should be made combining physical exam, laboratory tests, imaging and histology results, and include differentiation from other autoimmune, malignant and infectious causes. Based on the reviewed literature, it is advised to consider minimally invasive core biopsies in lupus patients over open biopsies as the associated trauma may exacerbate local inflammation. Conservative treatment with immunosupressive and anti-inflammatory drugs allows for control of breast symptoms in most cases.
- 12 January 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (3) , 320-328
Lupus mastitis heralding macrophage activation syndrome: Case report and systematic review of the literature
Objective: The purpose of this systematic review study was to showcase diagnostic challenges posed by lupus mastitis (LM). Methods: Here we report a case of a 47-year- old Caucasian female with LM heralding systemic lupus erythematosus (SLE) complicated by macrophage activation syndrome (MAS), in the light of a systematic review of the literature on LM. Results: Including our patient, we identified 32 case reports of patients with LM in the course of SLE. Only in 6 cases, including ours, LM preceded SLE diagnosis. Ours is the first ever published case report of LM heralding MAS. Conclusion: LM in the course of SLE is rare and published data is very limited. Diagnosis should be made combining physical exam, laboratory tests, imaging and histology results, and include differentiation from other autoimmune, malignant and infectious causes. Based on the reviewed literature, it is advised to consider minimally invasive core biopsies in lupus patients over open biopsies as the associated trauma may exacerbate local inflammation. Conservative treatment with immunosupressive and anti-inflammatory drugs allows for control of breast symptoms in most cases.
- Open Access
- 16 January 2025
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (10) , 1769-1781
Novel therapies in SLE treatment: A literature review
Systemic lupus erythematosus (SLE) is a chronic, autoimmune inflammatory disease with a multisystem manifestation and a variety of clinical symptoms. Over the last decades, the prognosis and life expectancy of patients with SLE improved significantly due to the implementation of corticosteroids combined with immunosuppressive agents. Nevertheless, the use of these medications is often associated with the occurrence of serious side effects and additional deterioration of organ function. Therefore, developing and implementing novel therapies that are both safer and more effective in managing disease is crucial. For a long time, European Alliance of Associations for Rheumatology (EULAR) recommended only 2 biological agents in the treatment of SLE: belimumab and rituximab. However, in 2023, anifrolumab, an interferon (IFN) receptor inhibitor, and voclosporin, a novel calcineurin inhibitor, appeared in new SLE treatment guidelines. In addition, several biological agents are targeting different cells or cytokines that are being evaluated in phase II and III clinical trials. Apart from that, experimental therapies such as targeting of plasma cells, chimeric antigen receptor T-cell therapy (CAR-T) or stem cell transplantation appear promising in the treatment of the severe forms of SLE.
- 16 January 2025
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (10) , 1769-1781
Open AccessNovel therapies in SLE treatment: A literature review
Systemic lupus erythematosus (SLE) is a chronic, autoimmune inflammatory disease with a multisystem manifestation and a variety of clinical symptoms. Over the last decades, the prognosis and life expectancy of patients with SLE improved significantly due to the implementation of corticosteroids combined with immunosuppressive agents. Nevertheless, the use of these medications is often associated with the occurrence of serious side effects and additional deterioration of organ function. Therefore, developing and implementing novel therapies that are both safer and more effective in managing disease is crucial. For a long time, European Alliance of Associations for Rheumatology (EULAR) recommended only 2 biological agents in the treatment of SLE: belimumab and rituximab. However, in 2023, anifrolumab, an interferon (IFN) receptor inhibitor, and voclosporin, a novel calcineurin inhibitor, appeared in new SLE treatment guidelines. In addition, several biological agents are targeting different cells or cytokines that are being evaluated in phase II and III clinical trials. Apart from that, experimental therapies such as targeting of plasma cells, chimeric antigen receptor T-cell therapy (CAR-T) or stem cell transplantation appear promising in the treatment of the severe forms of SLE.
- Open Access
- 18 September 2020
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 66 (3)
Ormond’s disease accompanied by ankylosing spondylitis – a case report
Idiopathic retroperitoneal fibrosis, or Ormond’s disease, is a rare syndrome which is in essence the deposition of pathological fibrous tissue in the retroperitoneal space. In most cases, it is initially asymptomatic, but as the disease progresses, clinical symptoms develop. The main complaint are abdominal pain and symptoms resulting from the involvement of ureters, arterial and venous vessels. Diagnosis is based on computed tomography or magnetic resonance imaging, demonstrating a fibrotic tissue mass accumulated in the retroperitoneal space. Due to the typically late presentation of clinical symptoms, a diagnosis is difficult and is often made after complications occur. In our article, we present the case of a 71-year-old patient in whom coexisting ankylosing spondylitis and retroperitoneal fibrosis were diagnosed 15 years after non-specific abdominal pain occurred.
- 18 September 2020
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 66 (3)
Open AccessOrmond’s disease accompanied by ankylosing spondylitis – a case report
Idiopathic retroperitoneal fibrosis, or Ormond’s disease, is a rare syndrome which is in essence the deposition of pathological fibrous tissue in the retroperitoneal space. In most cases, it is initially asymptomatic, but as the disease progresses, clinical symptoms develop. The main complaint are abdominal pain and symptoms resulting from the involvement of ureters, arterial and venous vessels. Diagnosis is based on computed tomography or magnetic resonance imaging, demonstrating a fibrotic tissue mass accumulated in the retroperitoneal space. Due to the typically late presentation of clinical symptoms, a diagnosis is difficult and is often made after complications occur. In our article, we present the case of a 71-year-old patient in whom coexisting ankylosing spondylitis and retroperitoneal fibrosis were diagnosed 15 years after non-specific abdominal pain occurred.